Alzheimer's Disease Pipeline Insight 2025: Therapeutic Landscape and Emerging Therapies

As the leading cause of dementia, Alzheimer's disease affects millions worldwide, with over 110 key companies actively developing more than 120 treatment therapies. DelveInsight's "Alzheimer's disease Pipeline Insight, 2025" report provides a comprehensive analysis of the clinical development activities and growth prospects across the Alzheimer's disease Therapeutics Market. The report highlights the dynamic landscape of Alzheimer's disease with novel treatments in various stages of development, from pre-clinical to Phase III clinical trials.

Key Takeaways:

• DelveInsight's Alzheimer's disease pipeline report highlights a dynamic landscape with over 110 active companies developing more than 120 potential therapies, including AR1001, NE3107, LY3372689, CT1812, ABBV-916, and ALX-001, among others.
• Leading players include AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical, and others.
• The U.S. FDA granted accelerated approval to Leqembi, an amyloid beta-directed antibody, in January 2023, followed by full FDA approval in July 2023, based on early evidence of clinical benefit and confirmed effectiveness in slowing cognitive decline in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
• The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's disease Market.
• It evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It provides detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer's disease market.

Statistics:

• Over 110 key companies are actively developing more than 120 treatment therapies for Alzheimer's disease.
• The U.S. FDA granted accelerated approval to Leqembi, an amyloid beta-directed antibody, in January 2023, followed by full FDA approval in July 2023.
• The Alzheimer's disease pipeline landscape includes over 200 companies and 220+ pipeline drugs.

Sources:

• DelveInsight's "Alzheimer's disease Pipeline Insight, 2025" report
• M2 PressWIRE-August 12, 2025-: Alzheimer's disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape (C)1994-2025 M2 COMMUNICATIONS RDATE:11082025